What the FDA labels say about taking them together
Sirolimus and voriconazole
Sirolimus's FDA label of January 28, 2026 names voriconazole in its drug interactions section, and voriconazole's label names sirolimus too. The voriconazole label: “Contraindicated”
Check it at the source: the sirolimus FDA label on DailyMed (effective January 28, 2026, Glenmark Pharmaceuticals Inc., USA); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the sirolimus label say about voriconazole?
Sirolimus label, drug interactionsInducers and Strong Inhibitors of CYP3A4 and P-gp Avoid concomitant use of sirolimus with strong inducers (e.g., rifampin, rifabutin) and strong inhibitors (e.g., ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, clarithromycin) of CYP3A4 and P-gp.
Sirolimus label, warnings and precautionsInhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions ( 7.2 ) ].
Source: FDA drug label (sirolimus), Glenmark Pharmaceuticals Inc., USA, effective January 28, 2026 (SPL set 57fb4d90-3ccb-4a69-af1e-53be83f7a504), via openFDA; the full label on DailyMed
What does the voriconazole label say about sirolimus?
Voriconazole label, contraindicationsSirolimus [see Clinical Pharmacology (12.3) ]
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Sirolimus Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Significantly Increased; Prevention or Management Recommendations: Contraindicated
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), contraindicationsCoadministration of Voriconazole for injection with sirolimus is contraindicated because Voriconazole for injection significantly increases sirolimus concentrations [see Drug Interactions (7) and Clinical Pharmacology (12.3) ].
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Sirolimus (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Significantly Increased; Recommendations for Drug Dosage Adjustment/Comments: Contraindicated
Source: FDA drug label (Voriconazole, NDA208562), Xellia Pharmaceuticals USA LLC, effective January 11, 2023 (SPL set 9ec6eda2-2f15-423b-9ec6-819379a426e1), via openFDA
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Sirolimus | Voriconazole | |
|---|---|---|
| Labeled for | Organ transplant rejection | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.723 per tablet 1 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once